FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021361323> ?p ?o ?g. }

• W3021361323 endingPage "2454.e5" @default.
• W3021361323 startingPage "2442" @default.
• W3021361323 abstract "The histone methylase EZH2 is frequently dysregulated in melanoma and is associated with DNA methylation and silencing of genes involved in tumor suppression. In this study, we used chromatin immunoprecipitation and sequencing to identify key suppressor genes that are silenced by histone methylation in constitutively active EZH2(Y641) mutant melanoma and assessed whether these regions were also sites of DNA methylation. The genes identified were validated by their re-expression after treatment with EZH2 and DNA methyltransferase inhibitors. The expression of putative EZH2 target genes was shown to be highly relevant to the survival of patients with melanoma in clinical datasets. To determine correlates of response to EZH2 inhibitors, we screened a panel of 53 melanoma cell lines for drug sensitivity. We compared RNA sequencing profiles of sensitive to resistant melanoma cells and performed pathway analysis. Sensitivity was associated with strong downregulation of IFN-γ and IFN-α gene signatures that were reversed by treatment with EZH2 inhibitors. This is consistent with EZH2-driven dedifferentiated invasive states associated with treatment resistance and defects in antigen presentation. These results suggest that EZH2 inhibitors may be most effectively targeted to immunologically cold melanoma to both induce direct cytotoxicity and increase immune responses in the context of checkpoint inhibitor immunotherapy. The histone methylase EZH2 is frequently dysregulated in melanoma and is associated with DNA methylation and silencing of genes involved in tumor suppression. In this study, we used chromatin immunoprecipitation and sequencing to identify key suppressor genes that are silenced by histone methylation in constitutively active EZH2(Y641) mutant melanoma and assessed whether these regions were also sites of DNA methylation. The genes identified were validated by their re-expression after treatment with EZH2 and DNA methyltransferase inhibitors. The expression of putative EZH2 target genes was shown to be highly relevant to the survival of patients with melanoma in clinical datasets. To determine correlates of response to EZH2 inhibitors, we screened a panel of 53 melanoma cell lines for drug sensitivity. We compared RNA sequencing profiles of sensitive to resistant melanoma cells and performed pathway analysis. Sensitivity was associated with strong downregulation of IFN-γ and IFN-α gene signatures that were reversed by treatment with EZH2 inhibitors. This is consistent with EZH2-driven dedifferentiated invasive states associated with treatment resistance and defects in antigen presentation. These results suggest that EZH2 inhibitors may be most effectively targeted to immunologically cold melanoma to both induce direct cytotoxicity and increase immune responses in the context of checkpoint inhibitor immunotherapy." @default.
• W3021361323 created "2020-05-13" @default.
• W3021361323 creator A5014685459 @default.
• W3021361323 creator A5018818153 @default.
• W3021361323 creator A5033366059 @default.
• W3021361323 creator A5034653278 @default.
• W3021361323 creator A5042462309 @default.
• W3021361323 creator A5045275728 @default.
• W3021361323 creator A5047057665 @default.
• W3021361323 creator A5052284583 @default.
• W3021361323 creator A5055038393 @default.
• W3021361323 creator A5062599999 @default.
• W3021361323 creator A5067671868 @default.
• W3021361323 creator A5067942807 @default.
• W3021361323 creator A5090852800 @default.
• W3021361323 date "2020-12-01" @default.
• W3021361323 modified "2023-10-14" @default.
• W3021361323 title "EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma" @default.
• W3021361323 cites W1029479003 @default.
• W3021361323 cites W1546905222 @default.
• W3021361323 cites W1834647529 @default.
• W3021361323 cites W1873710893 @default.
• W3021361323 cites W1966429292 @default.
• W3021361323 cites W1969485334 @default.
• W3021361323 cites W1976626368 @default.
• W3021361323 cites W1977621555 @default.
• W3021361323 cites W2004380688 @default.
• W3021361323 cites W2007169249 @default.
• W3021361323 cites W2018172915 @default.
• W3021361323 cites W2052313621 @default.
• W3021361323 cites W2053421436 @default.
• W3021361323 cites W2060608189 @default.
• W3021361323 cites W2073839391 @default.
• W3021361323 cites W2076166581 @default.
• W3021361323 cites W2094051261 @default.
• W3021361323 cites W2106262022 @default.
• W3021361323 cites W2116816603 @default.
• W3021361323 cites W2131232216 @default.
• W3021361323 cites W2131374955 @default.
• W3021361323 cites W2146862337 @default.
• W3021361323 cites W2158810118 @default.
• W3021361323 cites W2264682687 @default.
• W3021361323 cites W2291929727 @default.
• W3021361323 cites W2299181842 @default.
• W3021361323 cites W2558219863 @default.
• W3021361323 cites W2574813995 @default.
• W3021361323 cites W2600997873 @default.
• W3021361323 cites W2608289720 @default.
• W3021361323 cites W2611187032 @default.
• W3021361323 cites W2622569555 @default.
• W3021361323 cites W2726891392 @default.
• W3021361323 cites W2737220388 @default.
• W3021361323 cites W2752092162 @default.
• W3021361323 cites W2753432434 @default.
• W3021361323 cites W2761314488 @default.
• W3021361323 cites W2765224588 @default.
• W3021361323 cites W2766749796 @default.
• W3021361323 cites W2795058985 @default.
• W3021361323 cites W2797309423 @default.
• W3021361323 cites W2808419418 @default.
• W3021361323 cites W2895785343 @default.
• W3021361323 cites W2911966783 @default.
• W3021361323 doi "https://doi.org/10.1016/j.jid.2020.02.042" @default.
• W3021361323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32360600" @default.
• W3021361323 hasPublicationYear "2020" @default.
• W3021361323 type Work @default.
• W3021361323 sameAs 3021361323 @default.
• W3021361323 citedByCount "41" @default.
• W3021361323 countsByYear W30213613232020 @default.
• W3021361323 countsByYear W30213613232021 @default.
• W3021361323 countsByYear W30213613232022 @default.
• W3021361323 countsByYear W30213613232023 @default.
• W3021361323 crossrefType "journal-article" @default.
• W3021361323 hasAuthorship W3021361323A5014685459 @default.
• W3021361323 hasAuthorship W3021361323A5018818153 @default.
• W3021361323 hasAuthorship W3021361323A5033366059 @default.
• W3021361323 hasAuthorship W3021361323A5034653278 @default.
• W3021361323 hasAuthorship W3021361323A5042462309 @default.
• W3021361323 hasAuthorship W3021361323A5045275728 @default.
• W3021361323 hasAuthorship W3021361323A5047057665 @default.
• W3021361323 hasAuthorship W3021361323A5052284583 @default.
• W3021361323 hasAuthorship W3021361323A5055038393 @default.
• W3021361323 hasAuthorship W3021361323A5062599999 @default.
• W3021361323 hasAuthorship W3021361323A5067671868 @default.
• W3021361323 hasAuthorship W3021361323A5067942807 @default.
• W3021361323 hasAuthorship W3021361323A5090852800 @default.
• W3021361323 hasBestOaLocation W30213613231 @default.
• W3021361323 hasConcept C101762097 @default.
• W3021361323 hasConcept C104317684 @default.
• W3021361323 hasConcept C114691636 @default.
• W3021361323 hasConcept C134320426 @default.
• W3021361323 hasConcept C150194340 @default.
• W3021361323 hasConcept C150425827 @default.
• W3021361323 hasConcept C153911025 @default.
• W3021361323 hasConcept C190727270 @default.
• W3021361323 hasConcept C22709980 @default.
• W3021361323 hasConcept C2777658100 @default.
• W3021361323 hasConcept C41091548 @default.

• next